Date: 2026-08-10 Protocol: method/verification-protocol.md, Phase 1 Filing under check: Whitepaper No. 8, filed 2026-08-03 — site/drugs/index.html, site/drugs/sources/index.html, and the full research record in drugs/docs/ and drugs/research/. Independence (V1): run in a session that did not author the filing, did not run its red team, and did not run its blind re-score. The filing's own citations were treated as claims to be re-derived, not as verification.
Coverage numbers (V3)
| Count | |
|---|---|
| Claims extracted | 393 |
| Verdicts recorded | 393 |
| Unaddressed | 0 |
Breakdown: 122 from the public whitepaper, 63 from the public sources page, 208 from the research record that do not appear on the public pages.
Extraction-quality guardrail
Extraction was not delegated — it was performed directly by the adjudicating model, which is stronger than the protocol's minimum (the childcare lesson was that weak extractors silently drop inferential claims). The guardrail was still run against my own ledger: Part 2 of the whitepaper was independently re-extracted by mechanical sentence-split and diffed against the first-pass ledger. The diff found 2 misses out of 20 (10%), both of the same class — section headers and stamp text, which carry assertions (the best-evidenced treatments are the most legally cornered; Binding constraint) but sit outside body prose. That miss class was then swept across every section, adding 10 claims and taking the ledger from 383 to 393. Recording the rate rather than asserting completeness is the point of the check.
Verdict distribution
| Verdict | All | Whitepaper | Sources page | Record only |
|---|---|---|---|---|
| CONFIRMED (primary-verified) | 140 | 60 | 25 | 55 |
| CORRECTED | 23 | 10 | 8 | 5 |
| OVERSTATED | 34 | 23 | 4 | 7 |
| STALE | 11 | 5 | 3 | 3 |
| UNVERIFIABLE | 185 | 24 | 23 | 138 |
| Total | 393 | 122 | 63 | 208 |
Counts are computed from an explicit per-claim assignment, not estimated; the assignment partitions all 393 IDs with no duplicates and no gaps.
Two rules govern this distribution, and both should be read before the numbers are.
The cascade rule. A claim whose only defect is that one of its inputs could not be reached is marked UNVERIFIABLE, not CONFIRMED. So "alcohol deaths exceed the overdose peak by more than half" is U — the arithmetic is fine, but the 178,307 input is behind a 403. This is strict, and it is the protocol's rule (V2: re-derive every claim you examine from sources you fetch yourself). It means UNVERIFIABLE here measures this pass's reach at least as much as it measures the filing's sourcing.
Where the 185 sit. Three concentrations, none of them evenly spread. cdc.gov is comprehensively bot-blocked — 403 on the MMWR paths, the data briefs, and stacks.cdc.gov — so the alcohol and tobacco mortality figures stay at secondary tier, which is why the filing's own masthead verdict, "the legal drugs kill more," is UNVERIFIABLE by this pass. Not contradicted: unreached. That is worth saying plainly, because it is the single sentence the whitepaper leads with. Second, the criminology base under Part 4 (HOPE's replication, the Campbell drug-court review, the focused-deterrence systematic review) sits outside the indexes reachable here. Third, §7 and §8 rest on commercial trackers, watchdog 990 readings and state-agency data that have no deeper tier to push to — the filing labelled most of these moderate-confidence, and it was right to.
The number that carries real weight is the other one: 57 claims moved (23 CORRECTED, 34 OVERSTATED), and 18 of the 23 corrections are on the public pages. (These counts are post-audit: an independent adversarial audit on 2026-08-10 reversed this pass's own verdict on the June 2025 nowcasting artifact — see headline finding 3 and deviation #22 — moving A53, B11 and C14 from CORRECTED to CONFIRMED and A54 from UNVERIFIABLE to CONFIRMED.)
Headline findings
Seven items change what the public pages say. Ordered by how much they carry.
1. The filing's central recommendation rests on a legal mechanism that does not exist as described — CORRECTED
The whitepaper's abstract and Part 2 say contingency management (CM) is "capped … by a federal anti-kickback rule one agency could lift tomorrow" and "was capped for years at a third of its trial-effective incentive level by a federal anti-kickback policy one office can change on its own." Part 6 makes CM the top-ranked architecture and Part 7 makes it the filing's first move.
Three primary sources, fetched this pass, say otherwise:
- OIG's own final rule, 85 FR 77684 at 77791–92 (Dec. 2, 2020): "we are aware that some industry stakeholders may be under a misimpression that OIG prohibits contingency management program incentives above $75. There is no OIG-imposed $75 limitation on contingency management program incentives." The $15-per-item / $75-aggregate figure is nominal-value guidance under the Beneficiary Inducements CMP, and OIG states it "applies only with respect to the Beneficiary Inducements CMP and not to the Federal anti-kickback statute," and only to in-kind items, not cash.
- SAMHSA's own advisory (PEP24-06-001, Jan. 2025), the document the filing cites: the $75 constraint was a SAMHSA grant condition — "Previous SAMHSA Notice of Funding Opportunities limited per patient, per year CM incentive values to $75" — and SAMHSA describes the OIG-cap version as "the belief that certain guidance published by … OIG imposed a CM incentive value cap of $75 per patient, per year," which "HHS-OIG has clarified".
- 42 CFR 1001.952(hh)(5) (eCFR, current): the actual safe-harbor ceiling is a $500 base, CPI-indexed annual aggregate — $591 (2024), $605 (2025), $623 (2026) per OIG's published inflation-update table — and it is available only inside a value-based enterprise meeting nine conditions, in-kind only, no cash or cash equivalents.
So the barrier was not an anti-kickback cap one office could lift. It was a grant-program condition (already lifted, to $750, in January 2025) layered on top of a statute that OIG cannot repeal by rulemaking — it can only add a safe harbor, and only "in consultation with the Attorney General" (42 U.S.C. 1320a-7d(a)(1)(B)).
This was already found inside the filing's own record. ws14-cm-legal-status.md, dated 2026-08-06, records the same correction and says it "supersedes any statement that CM has a settled nationwide safe-harbor expansion or an OIG $75 'cap'." Deviation #20 logs it. The public pages were never updated. Four days of live whitepaper have carried a superseded legal claim as the filing's headline recommendation. This pass re-derived the correction independently from primary text rather than adopting ws14's conclusion, and it holds.
2. "A federal rulemaking process already underway" is not underway — CORRECTED / STALE
Part 2 says OIG "opened a formal review in November 2024"; Part 6 credits CM with "a federal rulemaking process already underway"; §11 calls it "already in motion."
- The November 2024 document is 89 FR 93545 (Nov. 27, 2024, comments closed Jan. 27, 2025). Its own text: "In accordance with section 205 of [HIPAA] … this annual notification solicits proposals." It is the statutorily mandated yearly solicitation under 42 U.S.C. 1320a-7d — OIG published one in 2022, 2023, 2024 and again in December 2025. It does not mention contingency management anywhere.
- The actual CM safe-harbor rulemaking is RIN 0936-AA13. On the current Unified Agenda it sits in Long-Term Actions with an NPRM target of July 2027. ws14 already recorded the slip from a May 2026 target; the current agenda entry confirms it.
Calling a mandatory annual notice "a formal review" of CM, and a rule with a 2027 target "already underway," is the CHARACTERIZATION failure mode (V4) applied to the filing's own recommendation.
3. The June 2025 "spike that wasn't" — CONFIRMED (this pass's own first verdict was wrong, and is reversed)
Part 3 says the June 2025 reversal "turned out to be a statistical artifact in CDC's own forecasting model — corrected months later." The anchor table cites this to Post & Ciccarone, AJPH 2025, at PMC13066679.
Citation fix (stands). The article is "The 2025 Drug Overdose Spike That Wasn't: Neither Politics nor Data Errors Explain the Anomaly," Am J Public Health 2026 May;116(5):591–593 (PMID 41950462, doi 10.2105/AJPH.2025.308412) — 2026, not 2025.
Substance (reversed). This pass first recorded the claim as CORRECTED/withdrawn, reasoning that the title asserted the opposite and that the body was paywalled. Both premises were false. The article is open access at https://pmc.ncbi.nlm.nih.gov/articles/PMC13066679/ and was fetched in full on 2026-08-10 by an independent adversarial audit and re-fetched to confirm. It says, verbatim:
"Instead, the anomaly was a model artifact"
"A second revision released in August 2025 … clarifying that the January 2025 'spike' was an artifact"
"the anomaly resulted from applying growth-era algorithms to a period of decline"
The title rules out political manipulation and coding/reporting error as the explanation — leaving the forecasting-model artifact, which is exactly what the filing said. The paper also records that neither administration had an apparent motive to inflate mortality.
Verdict: CONFIRMED at primary-source tier. The withdrawal is reversed on the public pages and in the ledger below. The failure mode was V-title-only: a verdict rendered on a title plus an unchecked paywall assumption, without fetching the body. Logged as deviation #22.
4. Methadone's OTP monopoly is not "written directly into statute" — OVERSTATED
The abstract says methadone is dispensable only through 2,000 clinics "by a statute Congress alone can change"; Part 2 calls it "a restriction written directly into statute (21 U.S.C. §823(h))."
21 U.S.C. §823(h) (current text, in the atlas at method/sources/usc21-823h-methadone-registration.md) requires practitioners dispensing narcotics for maintenance or detoxification treatment to obtain a separate annual registration, and directs the Attorney General to register applicants who meet standards established by the Secretary. It is facility-neutral on its face. It does not name opioid treatment programs, does not confine dispensing to them, and does not cap the number of them. The OTP-exclusive structure is built by SAMHSA's 42 CFR Part 8 certification regime and DEA's registration standards issued under that section.
SAMHSA's own 2024 final rule supports the narrower reading. Asked by commenters to allow community-pharmacy dispensing, SAMHSA did not say it lacked statutory authority — it said "The final 42 CFR part 8 rule only applies to dispensing of methadone in OTPs. SAMHSA continues to work with Federal partners to explore ways through which access to MOUD might be expanded."
The separate-registration requirement is statutory. The monopoly is the agencies' implementation of it. This matters beyond wording: §11 puts methadone deregulation in Tier 3 ("requires new statute") on the strength of this reading.
5. A quotation attributed to Spencer 2023 is not in Spencer 2023 — CORRECTED
ws09-oregon-findings.md states: "Spencer's own abstract attributes this to decriminalization occurring 'in a context… not accompanied by substantial public health investments'." The published abstract (J Health Econ 2023;91:102798, PMID 37556870) reads: "This paper evaluates the causal effect of drug decriminalization on unintentional drug overdose deaths in a context with relatively poor access to drug treatment services."
The substance survives — Spencer does locate the effect in a poor-treatment-access context, and the finding of 182 additional 2021 deaths (~23%) is confirmed verbatim. The quotation does not. Per the protocol's known traps, a figure or phrase never seen inside the fetched source is exactly what this pass exists to catch.
6. The Switzerland gap the honesty box says is open has been closed — and it closed against the filing — STALE
The honesty box says: "we haven't yet root-traced Switzerland, the case most often cited as the one that funded treatment properly. That comparison is still open."
ws12-switzerland-root-trace.md, dated 2026-08-06, ran that trace. Its verdict: REFUTES the use of Switzerland as a positive counterfactual — the Swiss model is a four-pillar framework that retains enforcement, and its exceptional intervention is heroin-assisted treatment for a treatment-refractory population (~1,700 people, ~8% of Swiss heroin users), not decriminalization. Finding 3: NOT MEASURED — "Retire the phrase 'Switzerland funded treatment properly'."
The record found something that weakens the filing's framing, and the public page still tells readers the question is open. ws12's own implementation note says the site edit was deferred because PR #39 was touching site/drugs/index.html; that PR is closed and the edit never landed.
7. Three numbers on the public pages disagree with each other and with the record — CORRECTED
- Deviations count. The whitepaper's receipts say "deviations log (14 entries)"; the sources page says 16 in two places;
deviations-log.mdhas 20. - Second-scorer status. The sources page document panel says "Status: Draft pending second scorer," while the whitepaper's Part 6 and honesty box both say the independent blind re-score is complete. The re-score landed 2026-08-04 (
ws10-rescore-log.md). - State-prison share. Part 4 says "89% of US prisoners are held" in state systems. BJS Prisoners in 2023 gives state 1,067,011 of 1,210,308 sentenced (88.2%); for yearend 2022, 1,070,834 of 1,230,143 (87.0%). The right figure is ~88%.
Secondary findings — recorded, no public change required
- The "~38%" decline. CDC VSRR provisional counts (data.cdc.gov
xkb8-kh2a, fetched 2026-08-10) put the 12-month-ending peak at 111,466 (June 2023) and the 12 months ending December 2025 at 69,939 — a 37.3% decline, so "~37–38%" (sources page) is right and "~38%" (whitepaper) rounds up. As of the check date (12 months ending February 2026, 67,531) the decline is 39.4%. Dual as-of verdict per V6: mildly overstated on the filing date, understated now. No correction needed; an as-of stamp is. - "Three of four peer-reviewed studies." Joshi (JAMA Psychiatry 2023, p=0.26) and Zoorob (JAMA Netw Open 2024) are confirmed. The third — "an April 2026 changepoint study" in Academia Global and Public Health — could not be located in any index; the record itself admits it was verified only through a secondary summary. Worse, its reported finding (Oregon's inflection at December 2019) conflicts with Zoorob's own changepoint analysis, which places Oregon's fentanyl escalation in the first half of 2021, contemporaneous with M110. And
ws13cites PMID 39235814 as a separate "2024 matrix-completion synthetic-control study" — that PMID is Zoorob. The count of independent Oregon nulls is 2 verified, not 3. - HOPE. The four-site replication null is real, but Humphreys & Kilmer published a peer-reviewed reconsideration — "Still HOPEful: Reconsidering a 'failed' replication…", Addiction 2020;115(10):1973–1977 — which the record never mentions. Part 4's "didn't survive its own replication" is stated more settled than the literature is, and the red team's Attack 4 ("does not land") was answered without this paper in view.
- The supply-shock story is contested in the record's own §13. Part 3's "two studies that actually decompose the cause" is undercut by Dasgupta et al., Fentanyl Purity and Overdose Decline: A Reexamination of Geographic Trends (medRxiv 2026, PMID 42078391 — a preprint, which ws13 does not flag), which finds the purity series does not track regional overdose increases and that the same associations appear with unrelated macroeconomic indicators. ws13's own instruction — "The national decline should therefore be described as multi-cause and unresolved" — was never applied to the public page.
- Cannabis, April 2026 — the filing got this right. This was the record's most-flagged unverified claim (
method/sources/UNOBTAINED.md§4 lists it as highest priority, never checked against primary text). Fetched this pass: 91 FR 22714, AG Order No. 6754-2026, dated April 22, 2026, effective April 28, 2026 — Schedule I→III for FDA-approved marijuana drug products and marijuana subject to a state medical-marijuana license; recreational unaffected; §280E discussed with the Administrator "encourag[ing] the Secretary of the Treasury to consider providing retrospective relief." The hearing notice (91 FR 22777) confirms the June 29–July 15, 2026 hearing. Three D.C. Circuit petitions confirmed on CourtListener: 26-1106 SAM, Inc. v. DOJ, 26-1130 Nebraska v. DOJ, 26-1136 New Directions v. Trump. §6's account is confirmed at primary tier — the "converging law-firm alerts" it relied on were accurate on scope, dates, the recreational carve-out, the §280E discussion and the hearing window. This is not verification in full: two elements were not independently found and must not be reported as confirmed — that the petitions were formally consolidated, and the August 17, 2026 post-hearing-brief deadline, which appears in neither Federal Register notice. Both require authenticated docket access. - BJS figures are right and were uncited. "131,300 of 1,039,500, yearend 2022" is verbatim BJS Prisoners in 2023 – Statistical Tables (Sept. 2025), p. 28 — the record never named the report. Federal 45% (2023) / 46% (2022) confirmed; the ~7.2× state:federal ratio computes to 7.24. This is the "true but unlanded" pattern the protocol names: fix the citation, don't withdraw the claim.
- Tanz et al. is exact. MMWR 2025;74(32):491–499 gives 59.0% stimulant-involved, 43.1% stimulant-and-opioid, cocaine 4.5→8.6 and psychostimulants 3.9→10.4 per 100,000 (2018–2023). Every figure in §3 matches. The public page drops ws03's own hedge ("arguably the modal death type without being an outright majority") when it says "the single largest overdose category" — accurate as a category comparison, thinner than the record's phrasing.
What could not be reached, and what was tried (V5)
| Target | Channels tried | Result |
|---|---|---|
| CDC alcohol-attributable deaths (178,307, 2020–21) | cdc.gov MMWR direct, stacks.cdc.gov, PubMed title search | 403 / 403 / no match. Figure remains secondary-tier only |
| CDC NCHS Data Brief 549 (54,743 opioid deaths; 88% fentanyl) | cdc.gov PDF | 403 |
| CDC tobacco mortality (450–480k) | cdc.gov | 403 |
| AJPH editorial body text (the "spike that wasn't") | PMC, Europe PMC fullTextXML, NCBI efetch db=pmc | Not open access; title + metadata only |
| Chua et al. NEJM 2024 figures (1,938 prescribers; 5,245 patients; 810–830k flat) | PubMed, PMC11103581 | Citation confirmed (N Engl J Med 2024;390(16):1530-1532) — but it is a Correspondence, not a full article, and the specific figures could not be read |
| April 2026 Oregon changepoint study | PubMed (multiple strings) | No index record. Consistent with the record's own admission |
| BJS yearend-2007 state drug-offender count (for "down 46%") | BJS p22st/p23st | Not in either; Prisoners in 2008 not retrieved |
| D.C. Circuit consolidation order; Aug 17 2026 briefing date | CourtListener v4 search + docket-entries | Entries endpoint requires authentication |
| Campbell drug-court review (154 evaluations, 38% vs 50%) | PubMed | Criminology coverage gap |
| Focused-deterrence 2025 systematic review (50 evaluations, 9 RCTs) | PubMed | Criminology coverage gap |
Retrieval notes worth carrying forward to other filings: data.cdc.gov's Socrata API serves the VSRR provisional overdose series cleanly over curl and is the working route around the cdc.gov block for mortality counts — it settled the peak and decline numbers that Phase 0 had to take from search summaries (deviation #3). library.samhsa.gov serves SAMHSA store PDFs after a 301 from store.samhsa.gov (follow redirects). reginfo.gov's eAgendaViewRule serves Unified Agenda entries directly and is the way to check whether a rulemaking is actually live.
The ledger
Verdict key: C = CONFIRMED · X = CORRECTED · O = OVERSTATED · U = UNVERIFIABLE · S = STALE. "as-of" columns per V6 are given only where the two differ.
A. Public whitepaper — site/drugs/index.html (122 claims)
| # | Claim | Verdict | Basis |
|---|---|---|---|
| A1 | Whitepaper No. 8, GBMT-8, filed 2026-08-03 | C | Repo record |
| A2 | Largest sustained decline in 40 years | C | Post et al., JAMA Netw Open 2025;8(6):e2514997 |
| A3 | Almost no policy anyone chose caused it | O | True of the two decomposition studies; contested by Dasgupta et al. 2026 |
| A4 | ~113,000 peak overdose deaths | C | VSRR peak 111,466 (12-mo ending Jun 2023) |
| A5 | The legal drugs kill more | U | Depends on A17/A18, both blocked by the cdc.gov 403. Unreached, not contradicted |
| A6 | Binding constraint is law, not evidence | O | Weakened by finding 1 — the CM leg of this claim does not hold |
| A7 | CM capped by a federal anti-kickback rule one agency could lift tomorrow | X | 85 FR 77791–92; SAMHSA PEP24-06-001; 42 CFR 1001.952(hh) |
| A8 | Methadone best-studied opioid treatment on Earth | U | No primary tier for a superlative |
| A9 | Dispensable only through 2,000 federally licensed clinics | C | ws04 two-source; ~2,000–2,100 OTPs |
| A10 | By a statute Congress alone can change | O | 21 U.S.C. §823(h) — see finding 4 |
| A11 | Fell ~38% from the 2023 peak | S | 37.3% at filing; 39.4% at check date |
| A12 | Explained by supply shock + shrinking at-risk population | O | Per ws13, describe as multi-cause and unresolved |
| A13 | Not by any program this filing could recommend | C | Dowell 2025; Vangelov 2026 |
| A14 | Portugal and Oregon are the two most-cited precedents | C | ws09, phase0 |
| A15 | Money arrived more than a year after leniency, both cases | U | Interval arithmetic checks (Feb 2021 → Jun 2022 = 16 months) but the disbursement date rests on ws09; Oregon SoS audit not retrieved |
| A16 | Cheapest first move is a federal rule change | X | Depends on A7; see finding 1 |
| A17 | ~178K alcohol deaths/yr | U | cdc.gov 403; secondary corroboration only |
| A18 | 450–480K tobacco deaths/yr | U | cdc.gov 403; secondary corroboration only |
| A19 | ~113K peak overdose deaths | C | VSRR 111,466 |
| A20 | 43.1% deaths involving both opioid & stimulant | C | MMWR 2025;74(32):491–499 |
| A21 | Alcohol figure is a CDC 2020–21 average | U | cdc.gov 403 |
| A22 | Alcohol exceeds overdose peak by more than half | U | Arithmetic holds (178,307 / 111,466 = 1.60); the numerator is unreached |
| A23 | Tobacco 4–7× peak overdose deaths | U | Arithmetic holds (450–480k / 111,466 = 4.0–4.3, and 4–7× against non-peak years); numerator unreached |
| A24 | Tobacco toolkit already in the architecture list | C | ws10 A9 row |
| A25 | Src line: CDC ARDI/MMWR 2024, tobacco estimates, Data Brief 549 | U | None retrievable |
| A26 | Two legal drugs kill more than the fentanyl era at its worst | U | Same dependency as A5 |
| A27 | Methadone has decades of evidence | C | Uncontested; ws04 |
| A28 | Dispensable via pharmacies in UK, Australia, Canada | C | ws04 two-source |
| A29 | US: only ~2,000 federally licensed clinics | C | ws04 |
| A30 | Restriction written directly into statute (§823(h)) | O | Finding 4 |
| A31 | Untouched by 2024's reform | C | 89 FR 7528: "only applies to dispensing of methadone in OTPs" |
| A32 | Waiver repeal produced real prescriber growth | C | ws04; Chua NEJM 2024 |
| A33 | Flat growth in patients treated | U | NEJM item is a Correspondence; figures unreadable |
| A34 | Confirmed by two independent studies | U | Second study (J. Addict. Med. 2025) not retrieved |
| A35 | The barrier wasn't the binding constraint | C | Consistent with A32/A33 direction |
| A36 | CM has the strongest evidence base for stimulant UD | C | OIG concurs: "the most effective currently available treatment for stimulant use disorders" (85 FR 77791) |
| A37 | Polysubstance now the single largest overdose category | O | True as category comparison; drops ws03's "without being an outright majority" |
| A38 | Capped for years at a third of trial-effective level | X | No cap as described; "a third" traces to nothing in the record |
| A39 | By a federal anti-kickback policy one office can change on its own | X | Finding 1; 1320a-7d(a)(1)(B) requires AG consultation |
| A40 | Src: 42 CFR Part 8 · Chua NEJM 2024 · PEP24-06-001 | C | All three exist; retrieved |
| A41 | Stamp: rulemaking-executable, no statute required | O | Safe harbor is rulemaking; the statute it shelters from is not |
| A42 | The CM fix is already in motion | X | RIN 0936-AA13 → Long-Term, NPRM 07/2027 |
| A43 | OIG has standing authority from a 1987 law | C | 42 U.S.C. 1320a-7d(a)(1)(A)(i) cites Pub. L. 100-93 §14(a) |
| A44 | Opened a formal review in November 2024 | X | 89 FR 93545 is the mandatory annual notice; no CM mention |
| A45 | Nothing about this needs Congress | O | A safe harbor doesn't; repealing the statutory exposure does |
| A46 | Peaked at ~112–114K in 2023 | C | Reported peak 111,466; nowcast-adjusted series runs higher |
| A47 | Fallen ~38% since | S | See A11 |
| A48 | Longest sustained decline in over 40 years | C | Post et al. 2025 |
| A49 | Exactly two studies decompose the cause quantitatively | O | Dasgupta et al. 2026 is a third analysis, contra |
| A50 | Both point to shrinking at-risk population + supply shock | C | Dowell 2025; Vangelov 2026 |
| A51 | Plausibly a Chinese precursor crackdown | C | Stated as plausible; Vangelov 2026 |
| A52 | Not naloxone/treatment, which are secondary and unisolated | C | ws03; both papers |
| A53 | June 2025 reversal was a CDC forecasting-model artifact | C | Post et al., AJPH 2026;116(5):591–593 (PMC13066679): "the anomaly was a model artifact" — see finding 3 |
| A54 | Corrected months later | C | Same source: "A second revision released in August 2025 … clarifying that the January 2025 'spike' was an artifact" |
| A55 | Src: … Post & Ciccarone, AJPH 2025 | X | AJPH 2026;116(5):591–593 |
| A56 | Deaths falling for reasons no policy here controls | C | ws03; ws11 |
| A57 | Real cocaine & heroin prices fell ~80% since 1981 | U | ONDCP/RAND STRIDE series not retrieved |
| A58 | 13% of state prisoners are drug offenders | C | BJS Prisoners in 2023, p. 28 |
| A59 | Down 46% since 2007 | U | BJS yearend-2007 baseline not retrieved |
| A60 | 89% of US prisoners held in state systems | O | 88.2% (2023); 87.0% (2022) |
| A61 | HOPE: 4-site replication found no advantage | C | Replication null real; see A66 for the settledness issue |
| A62 | Focused deterrence: RCT-confirmed for gang/gun violence, not drug markets | U | 2025 systematic review not retrieved |
| A63 | Drug courts 50%→38% recidivism | U | Campbell review not retrieved |
| A64 | Benefit concentrated among serious, dependent offenders | U | NIJ MADCE not retrieved |
| A65 | Stamp: steelman applied, not decorated | C | red-team.md Attack 4 |
| A66 | Enforcement's job is violence/reoffending, not price or supply | O | Overstates settledness of HOPE — Humphreys & Kilmer 2020 |
| A67 | Portugal HIV win genuine and strongly corroborated | U | Primary Portuguese/EMCDDA series not retrieved |
| A68 | Causal contribution "cannot be firmly established" | U | Hughes & Stevens PDFs unreachable (deviation #6 stands) |
| A69 | Most-cited pro-decrim US source is funded advocacy | U | Cato/MPP funding not verified at primary tier |
| A70 | Three of four peer-reviewed studies find little-to-no effect | O | 2 verified, 1 unlocatable — see secondary findings |
| A71 | They point to regional fentanyl timing | C | Zoorob 2024 |
| A72 | Funding didn't reach providers until 16 months after M110 took effect | U | Arithmetic checks; the June 2022 date was not re-derived from the Oregon audit |
| A73 | Both precedents broke identically | O | Rests on A70's count and on Portugal claims held at U |
| A74 | Src: Hughes & Stevens; Joshi; Zoorob; Spencer | C | Joshi, Zoorob, Spencer all verified as cited |
| A75 | Spencer 2023 finds a real Oregon effect | C | J Health Econ 2023;91:102798 — 182 deaths, 23% |
| A76 | Spencer attributes part of it to missing treatment buildout | C | Abstract: "a context with relatively poor access to drug treatment services" |
| A77 | Eleven architectures on eight dimensions | C | ws10 |
| A78 | The eight dimensions as listed | C | ws10 D1–D8 |
| A79 | Four objective weightings | C | ws10 |
| A80 | Top-ranked, confirmed by an independent blind second scorer | C | ws10-rescore-log.md (with disclosed leak) |
| A81 | CM has the strongest trial evidence in the filing | O | ws13: 2026 meta-analysis of 26 trials finds no overall retention effect; trials are pre-fentanyl-era |
| A82 | A federal rulemaking process already underway | X | Finding 2 |
| A83 | Next to no cost | C | ws10 D3 |
| A84 | Two first-pass claims withdrawn | C | ws10-rescore-log.md |
| A85 | Supply-side no longer ranks last | C | ws10 Σ16 vs A4/A9 Σ13 |
| A86 | Interdiction leg refuted by forty years of price data | U | Depends on A57 |
| A87 | Precursor leg carries the best observed link to the decline | O | Contested by Dasgupta et al. 2026 |
| A88 | Prevention row fell from second to bottom-tier | C | ws10-rescore-log.md (21→13) |
| A89 | Decrim and enforcement steelman show largest weighting swings | C | ws10 |
| A90 | Src: 11 × 8 × 4, anchored scales, red-team applied | C | ws10; 11×8 = 88 cells, 87 scored (A11 has no D1) |
| A91 | Stamp: clearest first move, not "the" recommendation | C | red-team Attack 2 amendment |
| A92 | Rulemaking-executable list: CM safe harbor, IMD waivers, settlement conditions | O | CM item depends on A42 |
| A93 | Can move in the next year with no new appropriation or statute | X | CM NPRM target is 07/2027 |
| A94 | Congress-required: methadone monopoly, cannabis banking | O | Methadone leg weakened by finding 4 |
| A95 | Oregon and SF reversed within two to four years | C | ws08; HB 4002 (2024); SF ordinance (Jul 2026) |
| A96 | By locally organized, donor-backed coalitions regardless of mortality data | C | ws08 |
| A97 | A politically invisible policy can bank results first | C | Argument, not fact claim; consistent with ws11 |
| A98 | Src: sequencing synthesis, 11 workstreams | S | Record now has 14 workstreams (ws12–ws14) |
| A99 | Scorecard dimensions favor cheap, fast fixes | C | red-team Attack 2 |
| A100 | Switzerland not yet root-traced; comparison still open | S | ws12 completed it 2026-08-06 — finding 6 |
| A101 | Independent blind second scorer has re-scored every cell | C | ws10-rescore-log.md, 87 cells |
| A102 | Reconciliation withdrew two claims and confirmed the headline | C | ws10-rescore-log.md |
| A103 | A status line leaked the headline to the second scorer | C | Disclosed in ws10-rescore-log.md |
| A104 | 11-workstream protocol | S | See A98 |
| A105 | Pre-registered adjudication criteria (M3) | O | Deviation #13: scoring method "was set by the synthesizing session's judgment, not pre-registered" |
| A106 | Anchor table preserving corrected priors | C | research-inquiry.md §3 |
| A107 | Deviations log (14 entries) | X | 20 entries |
| A108 | Red team applied | C | red-team.md |
| A109 | Steelman built for enforcement per M3 | C | ws05 H5.3; A10 row |
| A110 | All committed and public | C | Repo |
| A111 | Meta description: falling for reasons almost no policy caused | O | Same basis as A3 |
| A112 | Rail links (PDF, sources, corrections) | C | Files present |
| A113 | Part 1 header: alcohol and tobacco kill more than the whole overdose crisis | U | Same dependency as A5 |
| A114 | Part 2 header: best-evidenced treatments are the most legally cornered | O | CM leg fails per finding 1 |
| A115 | Part 2 stamp: "Binding constraint" | O | Same |
| A116 | Part 3 header: "The decline nobody caused" | O | Same basis as A3/A49 |
| A117 | Part 4 header: what enforcement buys and doesn't | C | ws05 |
| A118 | Part 5 header: "The precedents, root-traced" | C | ws09, phase0 |
| A119 | Part 5 stamp: "Contested, not settled" | C | ws09 |
| A120 | Part 6 header: eleven designs, four scorings, one first move | C | ws10 |
| A121 | Part 7 header: the cheap fix moves first | C | ws11 |
| A122 | Part 3 stamp: "Strong comparator, not a strawman" | C | ws10 A11 row; ws11 |
B. Public sources page — site/drugs/sources/index.html (63 claims)
| # | Claim | Verdict | Basis |
|---|---|---|---|
| B1 | Series GBMT-8, filed 2026-08-03 | C | Repo |
| B2 | Scope statement | C | research-inquiry.md |
| B3 | Imports M1–M9 in full | C | Pre-M10 filing; correctly not retrofitted |
| B4 | Phase 0 verdict GO | C | phase0-findings.md |
| B5 | 11 workstreams executed 2026-08-03 | S | 14 now exist |
| B6 | Workstream list | C | Files present |
| B7 | Red team applied four amendments before publication | C | red-team.md |
| B8 | Peak ~112–114k in 2023 | C | VSRR 111,466 (Jun 2023) |
| B9 | Cumulative decline ~37–38% | C | 37.3% at filing |
| B10 | "Largest on record" confirmed via Post et al. JAMA Netw Open 2025 | C | 2025;8(6):e2514997 verified |
| B11 | June 2025 reversal was a CDC nowcasting-model artifact, later corrected | C | Post et al., AJPH 2026 body fetched; finding 3 |
| B12 | "1 in 10" is a decade-stale 2015 root | U | NSDUH primary tables not retrieved |
| B13 | 2024 rate is 12.4–19.3% | U | Same |
| B14 | Perceived need 3.3–6.6% replicates | U | Same |
| B15 | Federal drug budget $44.2–44.5B FY23–25 | U | ONDCP PDFs not retrieved |
| B16 | Split ~55/45 demand-majority | U | Same |
| B17 | Historical 65–71% supply-side | U | Same |
| B18 | No unified state/local accounting; one 1990–91 survey | U | Negative claim; Census survey not retrieved (V5: cannot be CONFIRMED) |
| B19 | Anchor 4 prior (13–15% state, ~45% federal, ~7× ratio) | C | BJS: 13%, 45–46%, 7.24× |
| B20 | Portugal HIV ~1,287→16 | U | Primary series not retrieved |
| B21 | Death data incompatible across sources | U | Same |
| B22 | Greenwald/Cato 2009 confirmed funded advocacy | U | Funding not verified at primary tier |
| B23 | 3 of 4 studies find no detectable effect | O | 2 verified |
| B24 | Spencer dissent; funds didn't disburse until 16 months after | C | Spencer verified; timing verified |
| B25 | France 79–80% single-root (Auriacombe 2004) | U | Paywalled (deviation #7 stands) |
| B26 | French GP buprenorphine fell 43.8% 2009–2015 | U | Not retrieved |
| B27 | Methadone now France's leading substitution-drug-death cause | U | DRAMES not retrieved |
| B28 | Anchor 8 queued, not verified | C | Honest disclosure; accurate |
| B29 | CM capped at ~$75–599/yr by anti-kickback rules | X | Finding 1 |
| B30 | The cap is OIG subregulatory policy, not statute | X | OIG: no OIG-imposed CM limit; $75 was a SAMHSA grant condition |
| B31 | Alcohol ~178,307/yr; tobacco 450–480k | U | cdc.gov 403 |
| B32 | Methadone only via ~2,000 OTPs; peers use pharmacies | C | ws04 |
| B33 | Restriction written into §823(h), untouched by the 2024 reform | O | Finding 4; second half CONFIRMED |
| B34 | Settlements $50–58.6B depending on tracker | U | Trackers are secondary by nature |
| B35 | Only 12 states commit to detailed public reporting | U | Same |
| B36 | Real prices fell ~80% since 1981 | U | See A57 |
| B37 | Alcohol+tobacco exceed peak overdose by 1.5–4× | U | Arithmetic holds; inputs unreached |
| B38 | 6.9% of rural counties had a Medicare-enrolled OTP in 2022 | U | HHS OIG report not retrieved |
| B39 | ~3× spending disagreement ($13.1B vs $34–42B) | C | Reported as an open dispute — appropriate |
| B40 | Polysubstance 43.1% is the single largest category | C | MMWR 2025;74(32) |
| B41 | Two decomposition studies point supply/exposure-side | O | See A49 |
| B42 | Waiver repeal: prescriber growth, flat patients, two studies | U | See A33/A34 |
| B43 | CM anti-kickback cap raised 10× Jan 2025 (SAMHSA, grants only) | X | It was SAMHSA's own grant cap, not an anti-kickback cap |
| B44 | Every binding constraint examined is federal | C | ws06; verified for CSA scheduling, §823(h), 1001.952 |
| B45 | Narrow Schedule III order April 2026, active D.C. Circuit litigation, not legalization | C | 91 FR 22714; 3 petitions on CourtListener |
| B46 | CM cap is OIG subregulatory policy with a process already underway | X | Findings 1 and 2 |
| B47 | 12 states reporting; $61M+ to law enforcement in 2024 | U | KFF/Hopkins tracker is the primary tier available; not retrieved |
| B48 | CA/WA 50–60% illicit | U | State agency data not retrieved |
| B49 | Buprenorphine 14–50× pain-vs-OUD disparity | U | Not retrieved |
| B50 | Oregon and SF reversed within 2–4 years | C | ws08 |
| B51 | 3 of 4 studies; dissent locates harm in missing funding | O | See B23 |
| B52 | CM ranks first or tied-first under 3 of 4 weightings | C | ws10 |
| B53 | Supply-side ranks last under every weighting | X | Withdrawn by the re-score (ws10-rescore-log.md); page never updated |
| B54 | Decrim and enforcement steelman show largest rank instability | C | ws10 |
| B55 | Public-order durability runs on a 2–4 year clock | C | ws08/ws11 |
| B56 | Deviations log: 16 entries | X | 20 |
| B57 | Deviation summary rows 1–13 | C | Match deviations-log.md entries 1–13 |
| B58 | Five red-team attacks | C | red-team.md |
| B59 | Independent second scorer remains a standing requirement | S | Delivered 2026-08-04 |
| B60 | Four-site replication found no advantage | C | See A61 |
| B61 | Switzerland not yet root-traced | S | ws12, 2026-08-06 |
| B62 | Receipts: deviations log (16 entries) | X | 20 |
| B63 | Status: Draft pending second scorer | X | Re-score completed 2026-08-04 |
C. Research record only (208 claims)
Given in explicit ID sets so the partition is checkable: the five sets below are disjoint and their union is C1–C208.
CORRECTED — 5. (Was 6; C14 moved to CONFIRMED by the 2026-08-10 audit — deviation #22.)
- C77 — "Anti-kickback 'nominal value' guidance capped in-kind incentives at $75/patient/year." It is Beneficiary-Inducements-CMP guidance, not anti-kickback, and OIG states it is not a CM cap. (C79 — SAMHSA's January 2025 move to $750, grants only, in-kind only — is CONFIRMED verbatim against PEP24-06-001; it is the attribution in C77 that fails.)
- C102 — "three petitions … were consolidated in the D.C. Circuit." Three petitions confirmed (26-1106, 26-1130, 26-1136); consolidation not confirmable without authenticated docket access.
- C149 — the April 2026 changepoint study. Unlocatable in any index; its December-2019 inflection conflicts with Zoorob 2024's own changepoint result (fentanyl escalation in H1 2021); and "14 months before M110 even passed" is wrong — December 2019 to the November 2020 vote is 11 months. 14 months is the interval to implementation, which is what the anchor table says.
- C151 — the Spencer quotation. See headline finding 5.
- C189 — cites PMID 39235814 as a separate "2024 matrix-completion synthetic-control study." That PMID is Zoorob 2024, already counted at C148. The Oregon null literature is double-counted by one.
OVERSTATED — 7. C51, C53 (Dowell's and Vangelov's decomposition results stated more firmly than ws13 itself allows once Dasgupta et al. 2026 is in view); C93, C94 (HOPE — the Humphreys & Kilmer 2020 reconsideration is nowhere in the record); C116 (MOTAA's existence shows a statutory route was chosen, not that it was required — see headline finding 4); C157 (the Joshi null was published late September 2023, not "by mid-2023"; the operative point — before the 2024 session — holds); C207 (ws10's A3 basis text calls the Nov 2024 annual solicitation "already mid-process").
STALE — 3. C13 (CY2025 = 69,973 in the record; the current VSRR extract gives 69,939 — a provisional revision, not an error); C205 (the standing second-scorer requirement was discharged 2026-08-04); C208 (ws12's implementation note defers the site edit because "open PR #39 touches site/drugs/index.html" — #39 is closed and the edit never landed).
CONFIRMED — 55. Verified at primary tier this pass: C12 (CY2024 vs VSRR 80,860); C44–C46 (Tanz, MMWR 2025;74(32):491–499); C60, C61 (89 FR 7528); C79 (PEP24-06-001); C82, C85, C86 (BJS Prisoners in 2023); C99–C101, C103, C105 (91 FR 22714 / 91 FR 22777); C112 (Dec. 7, 2016 policy statement); C114 (89 FR 93545); C115 and C172 (Pub. L. 100-93 §14(a) via 42 U.S.C. 1320a-7d(a)(1)(A)(i)); C147, C148, C150 (Joshi, Zoorob, Spencer); C181 ($750 and the $605 2025 safe-harbor figure); C187 (Dasgupta et al., PMID 42078391 — noting it is a preprint, which ws13 does not say); C190–C194 (all four of ws14's legal statements, each independently re-derived); C195 (20 deviations entries); C14 (the nowcasting artifact — see finding 3; this pass's own first verdict on it was wrong and is reversed). Verified as accurate descriptions of the committed record: C160–C171 (scorecard and sequencing — the reconciled Σ values were re-added and check: A3 20; A5, A10, A11 18; A7 17; A2, A8 16; A1 15; A6 14; A4, A9 13; A11's per-dimension mean is 18/7 = 2.571 against A3's 20/8 = 2.500, so the "edges A3" claim is arithmetically right); C179 (ws12's REFUTES verdict); C182; C196–C204; C206.
UNVERIFIABLE — 138. C1–C11, C15–C43, C47–C50, C52, C54–C59, C62–C76, C78, C80, C81, C83, C84, C87–C92, C95–C98, C104, C106–C111, C113, C117–C146, C152–C156, C158, C159, C173–C178, C180, C183–C186, C188. These break into the three groups named under the verdict distribution: CDC-attributed figures behind the 403; the criminology and clinical literature not reachable from here; and the commercial/watchdog/state-agency material in §2, §7 and §8 that has no deeper tier. Four deserve individual mention because the filing itself flagged them and this pass could not close them either: C7–C10 (Portugal's primary sources — deviation #6 stands), C15–C17 (France's Auriacombe root — deviation #7 stands), C67–C68 (the Chua figures: the citation is confirmed as N Engl J Med 2024;390(16):1530-1532, but it is a Correspondence, and the 1,938 / 5,245 / 810–830k figures could not be read from it), and C152–C154 (Oregon's disbursement timeline, which carries headline claim A15).
Corrections applied on this branch
Per the corrections protocol, in dependency order — findings file → anchor table → scorecard basis → both public pages.
ws04-findings.md— CM anti-kickback section rewritten to the primary-source position.ws06-findings.md— CM ceiling and "process underway" corrected; methadone statutory characterization narrowed.ws09-oregon-findings.md— Spencer quotation corrected to the published abstract; the April 2026 changepoint study downgraded and its arithmetic fixed.ws03-findings.md— Post & Ciccarone citation corrected to AJPH 2026. (The nowcasting attribution was withdrawn here and then restored the same day — see finding 3 and deviation #22; the AJPH 2026 body is open access and confirms the artifact explanation.)research-inquiry.mdanchor table — rows 1, 9 and 11 corrected.ws10-findings.md— A3's basis text corrected (it cited the "Nov 2024 solicitation" as a live CM process).site/drugs/index.html— abstract, Part 2, Part 3, Part 6, Part 7, honesty box, receipts.site/drugs/sources/index.html— anchors 1/9/11, §4, §6, §10, deviations count, red-team Attack 5, document status.deviations-log.md— entry 21 (this pass).
Corrections are made in the open, per the protocol and the GBMT-2/GBMT-10 precedent. The whitepaper's scorecard rank order is not changed by this pass — that is a Phase 2 / re-score question. What changes is the basis text under A3 and the legal claims the public pages make about it. A3's D2 ("legal executability = 3, achievable via existing agency rulemaking alone") and D8 ("speed = 3, effects within ~1 year") are now visibly contradicted by RIN 0936-AA13's July 2027 NPRM target, and this log records that as owed to the next re-score rather than silently re-scoring a cell here.
Sources fetched and cached
Added to the atlas under method/sources/ this pass: oig-contingency-management-and-safe-harbors.md (85 FR 77684 at 77791–92; 42 CFR 1001.952(hh); OIG inflation table; 89 FR 93545; RIN 0936-AA13; SAMHSA PEP24-06-001) and dea-2026-marijuana-schedule-iii-order.md (91 FR 22714; 91 FR 22777; 91 FR 22778; the three D.C. Circuit dockets). Both carry the provenance header the atlas requires.